AMSTERDAM (NETHERLANDS) (ITALPRESS) – “A warning about unusual blood clots with low platelets should be added to the product information for the COVID-19 Janssen vaccine. The PRAC also concluded that these events should be listed as very side effects. rare of the vaccine “. The long-awaited pronouncement of the Safety Committee (PRAC) of the European Medicines Agency (EMA) on the vaccine produced by Janssen (Johnson & Johnson group) has arrived. The analysis started after the temporary stop of the US FDA for some rare suspected cases of thrombosis in vaccinees, similar to those seen for AstraZeneca: “In reaching its conclusion, the Committee considered all the evidence currently available, including eight reports from the United States of severe cases of unusual blood clots associated with low platelet levels, one of which was fatal. As of April 13, 2021, over 7 million people had received Janssen’s vaccine in the United States. ” As happened for AstraZeneca, the EMA underlines that “the benefits of the vaccine continue to outweigh the risks for the people who receive it. The vaccine is effective in preventing COVID-19 and reducing hospitalizations and deaths”. (ITALPRESS). tre / sat / red 20-Apr-21 16:40
COPYRIGHT today © breaking latest news